In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 319 for your search:
Drug:  bevacizumab
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEMCAD-1006, NCT01493713

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO25757, 2011-002009-31, NCT01588184

3.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25753, NCT01588990

4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28419, NCT01695772

5.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: YZHANG0001, NCT01962376

6.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000536013, MRC-ST03, EU-20710, ISRCTN46020948, 2006-000811-12, 00316/0221/001, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203

7.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-GFPC-0701, NCT00651456

8.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TG4010.14/TIME, 8559, NCT01383148

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00587, CDR0000546714, GOG-0213, U10CA027469, NCT00565851

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00507, CDR0000582533, E1305, U10CA021115, ECOG-E1305, NCT00588770

11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-000354-31, NCT00646607

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01952, CDR0000649174, CALGB 90601, U10CA031946, NCT00942331

13.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000649817, S0819, U10CA032102, SWOG-S0819, NCT00946712

14.

Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-01738, CDR0000659024, GOG-0250, U10CA027469, NCT01012297

15.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000666482, ECOG-E5508, E5508, NCT01107626

16.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRCA-CCTC-WCTU-ARTemis, CCTC-WCTU-ARTemis, ISRCTN68502941, EUDRACT-2008-002322-11, EU-21017, MREC-08/H1102/104, NCT01093235

17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22923, 2010-019525-34, NCT01239732

18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ML22011, NCT01249638

19.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 70 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000692257, NCCTG-N0949, N0949, NCT01279681

20.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-26101, EU-21103, 2010-023218-30, ROCHE-EORTC-26101, EUDRACT-2010-023218-30, NCT01290939

21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22097, NCT01351415

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAIRO4, NCT01606098

23.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: TTD-12-01, 2012-000846-37, NCT01640405

24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: PLA304DN-001, NCT01661790

25.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: OBELICS, 2011-004997-27, NCT01718873
1     
New Search